Cannabinoid CB 1 receptors (CB 1 Rs) mediate the presynaptic effects of endocannabinoids in the central nervous system (CNS) and most behavioral effects of exogenous cannabinoids. Cannabinoid receptor-interacting protein 1a (CRIP 1a ) binds to the CB 1 R C-terminus and can attenuate constitutive CB 1 R-mediated inhibition of Ca 21 channel activity. We now demonstrate cellular colocalization of CRIP 1a at neuronal elements in the CNS and show that CRIP 1a inhibits both constitutive and agonist-stimulated CB 1 Rmediated guanine nucleotide-binding regulatory protein (G-protein) activity. Stable overexpression of CRIP 1a in human embryonic kidney (HEK)-293 cells stably expressing CB 1 Rs (CB 1 -HEK), or in N18TG2 cells endogenously expressing CB 1 Rs, decreased CB 1 Rmediated G-protein activation (measured by agonist-stimulated [ activation. These effects were not attributable to differences in CB 1 R expression or endocannabinoid tone because CB 1 R levels did not differ between cell lines varying in CRIP 1a expression, and endocannabinoid levels were undetectable (CB 1 -HEK) or unchanged (N18TG2) by CRIP 1a overexpression. In CB 1 -HEK cells, 4-hour pretreatment with cannabinoid agonists downregulated CB 1 Rs and desensitized agonist-stimulated [ 35 S]GTPgS binding. CRIP 1a overexpression attenuated CB 1 R downregulation without altering CB 1 R desensitization. Finally, in cultured autaptic hippocampal neurons, CRIP 1a overexpression attenuated both depolarizationinduced suppression of excitation and inhibition of excitatory synaptic activity induced by exogenous application of cannabinoid but not by adenosine A1 agonists. These results confirm that CRIP 1a inhibits constitutive CB 1 R activity and demonstrate that CRIP 1a can also inhibit agonist-stimulated CB 1 R signaling and downregulation of CB 1 Rs. Thus, CRIP 1a appears to act as a broad negative regulator of CB 1 R function.
Introduction
Cannabinoid CB 1 receptors (CB 1 Rs) mediate most central nervous system (CNS) effects of the phytocannabinoid D 9 -tetrahydrocannabinol (THC) and the endocannabinoids (Howlett et al., 2002) . CB 1 Rs are guanine nucleotide-binding regulatory protein (G-protein)-coupled receptors (GPCRs) that primarily activate G i/o proteins (Howlett et al., 2002) and are widely distributed throughout the CNS (Herkenham et al., 1991) . CB 1 Rs mediate synaptic plasticity via inhibition of neurotransmitter release (Kano et al., 2009 ) and regulate memory/cognition, motor activity, motivation, anxiety, appetite, and energy balance (Howlett et al., 2002) . Thus, in addition to mediating abuserelated effects of cannabinoids, CB 1 Rs are attractive, albeit challenging, targets for drug discovery for the treatment of multiple CNS disorders (Pacher et al., 2006) . However, prolonged CB 1 R activation by direct agonists produces tolerance, dependence, perturbation of transcription factors, and CB 1 R adaptation (Smith et al., 2010; Lazenka et al., 2013) . Therefore, there is a need to better understand the regulation of CB 1 R signaling.
CB 1 Rs also interact with regulatory proteins that modulate CB 1 R function and mediate downstream signaling (Howlett et al., 2010; Smith et al., 2010) . These proteins include such ubiquitous GPCR regulators as GPCR kinase-3 (GRK3) and b-arrestin2, which mediate CB 1 R desensitization and intracellular trafficking (Jin et al., 1999; Nguyen et al., 2012) . Proteins that interact with a limited subset of receptor types include GPCRassociated sorting protein-1 (GASP1) and AP-3, which mediate CB 1 R targeting to lysosomes (Martini et al., 2007; Rozenfeld and Devi, 2008) . In addition, CB 1 Rs interact with specific cannabinoid receptor-interacting proteins CRIP 1a and CRIP 1b , which are not known to interact with any other GPCR (Niehaus et al., 2007) .
CRIP 1a/b interact with the last nine amino acids of the CB 1 R C-terminus, but not with the CB 2 R (Niehaus et al., 2007) . Both CRIP 1a/b proteins are encoded by the Cnrip1 gene, which contains four exons: 1, 2, 3a, and 3b. Alternative splicing produces transcripts comprising exons 1, 2, and 3a (CRIP 1a ) or 1, 2, and 3b (CRIP 1b ). CRIP 1a homologs are found throughout vertebrates, whereas CRIP 1b appears to be limited to primates (Niehaus et al., 2007) . The search for CB 1 R C-terminalinteracting proteins was initiated because this region exhibited autoinhibition of constitutive (agonist-independent) CB 1 R activity, which was relieved by truncation of the distal C-terminus of the receptor (Nie and Lewis, 2001a,b) . Indeed, electrophysiological recordings in superior cervical ganglion (SCG) neurons showed that expression of CRIP 1a , but not CRIP 1b , attenuated constitutive CB 1 -mediated inhibition of calcium channels, revealed by elimination of the inverse agonist activity of rimonabant (SR141716A). However, coexpression of CRIP 1a and CB 1 Rs did not alter agonist-induced inhibition of calcium currents or CB 1 R expression levels (Niehaus et al., 2007) , suggesting that CRIP 1a inhibits constitutive CB 1 R activity.
CRIP 1a is highly expressed in the brain (Niehaus et al., 2007) , and some reports suggest that CRIP 1a is regulated by seizure activity. Sclerotic hippocampi from epileptic patients exhibited reduced expression of mRNA for both CRIP 1a and CB 1 R (Ludanyi et al., 2008) . In contrast, CRIP 1a mRNA was elevated in rat hippocampus and cortex following kainic acidinduced seizures (Bojnik et al., 2012) . These findings suggest CRIP 1a involvement in modulating CB 1 R function in the pathogenesis or neuroadaptive response to epilepsy. Furthermore, CRIP 1a expression inhibited the neuroprotective effects of a cannabinoid agonist and conferred a neuroprotective effect on an antagonist, in a cultured neuronal model of glutamate excitotoxicity (Stauffer et al., 2011) . To date, evidence supports functional interactions between CRIP 1a and CB 1 R in striatal GABAergic medium spiny neurons (Blume et al., 2013) , glutamatergic hippocampal neurons (Ludanyi et al., 2008) , and retinal presynaptic terminals (Hu et al., 2010) . In addition, the Cnrip1 gene is hypermethylated in certain colorectal cancers (Lind et al., 2011; Oster et al., 2011) , further suggesting potentially important functions of CRIP 1a in multiple physiologic systems.
Despite the potential significance of CRIP 1a as a novel player in the endocannabinoid system, relatively little is known about its function. The present study determined the effects of CRIP 1a on constitutive and agonist-stimulated G-protein activation in CB 1 R-expressing cells. Because CRIP 1a binds to the CB 1 R C-terminus, which interacts with regulatory proteins that mediate CB 1 R desensitization and downregulation, the effects of CRIP 1a on prolonged agonist-induced adaptation in CB 1 R expression and signaling were also examined. To examine colocalization of CRIP 1a with CB 1 Rs in a defined neuronal population in the CNS, colabeling studies were conducted in the cerebellum because both proteins are highly expressed in this region (Herkenham et al., 1991; Niehaus et al., 2007) and it plays a major role in cannabinoid dependence (Tzavara et al., 2000) . Finally, to investigate the effects of CRIP 1a on endocannabinoid function, its influence on depolarizationinduced suppression of excitation (DSE) was examined in autaptic hippocampal neurons. [[(6S,6aR,9R,10aR )-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate], 7, 10, d] pyran-9-methanol], noladin ether, and SR141716A [5-(4-chlorophenyl)-1 (2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide] were provided as solutions in ethanol by the Drug Supply Program of the National Institute on Drug Abuse (NIDA, Rockville, MD). Methanandamide was purchased from Cayman Chemical (Ann Arbor, MI). LI-COR Odyssey infrared dye secondary antibodies were purchased from LI-COR Biosciences (Lincoln, NE). a-Tubulin antibody was purchased from Santa Cruz Biotechnology (Dallas, TX). All other reagent-grade chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
Materials and Methods

Chemicals
Stable Transfection and Treatment of Cultured Cells. Human embryonic kidney (HEK) 293 cells stably expressing the human CB 1 R subcloned into pcDNA3 vector (hCB 1 -HEK) (Abood et al., 1997) were cultured in Dulbecco's modified Eagle's medium (DMEM), 1Â high glucose containing 10% fetal bovine serum (FBS), 100 IU/ml penicillin, 100 mg/ml streptomycin (P/S), 0.25 mg/ml geneticin (G418), and 15 mM HEPES. hCB 1 -HEK cells stably cotransfected with CRIP 1a subcloned into the pcDNA3.1zeo vector (hCB 1 -HEK-CRIP 1a )
ABBREVIATIONS: 2-AG, 2-arachidonoylglycerol; 2-AGE, 2-arachidonoylglycerol ether; AEA, arachidonoylethanolamide; ANOVA, analysis of variance; BSA, bovine serum albumin; CB 1 R, cannabinoid CB 1 receptor; CNS, central nervous system; CP55,940, (2)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl) phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol; CPA, cyclopentyladenosine; DMEM, Dulbecco's modified Eagle's medium; DSE, depolarization-induced suppression of excitation; EPSC, excitatory postsynaptic current; FBS, fetal bovine serum; G418, geneticin; GPCR, G-protein-coupled receptor; GST, glutathione S-transferase; GTPgS, guanylyl-59-[O-thio]-triphosphate; HA, hemagglutinin; HEK, human embryonic kidney; 7, 10, ir, immunoreactivity; levonantradol, [(6S, 6aR, 9R, 6, 6a, 7, 8, 9, 10, acetate; MAEA, methanandamide; PBS, phosphate-buffered saline; P/S, penicillin/streptomycin; PTX, pertussis toxin; SCG, superior cervical ganglion; siRNA, small-interfering RNA; SR141716A, rimonabant, 5-(4-chlorophenyl)-1 (2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide; SV2, synaptic vesicle 2; THC, D 9 -tetrahydrocannabinol; WIN55,212-2, [(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone. (Niehaus et al., 2007) were cultured in the same media with the addition of 0.1 mg/ml zeocin.
Stable CRIP 1a -overexpression and -knockdown N18TG2 cell clones were generated by transfecting (Lipofectamine 2000; Invitrogen, Carlsbad, CA) N18TG2 cells with either a pcDNA3.1-CRIP 1a mouse cDNA plasmid for overexpression, or two different pRNATin-H1.2 small-interfering RNA (siRNA)-CRIP 1a vectors for knockdown. The GenScript siRNA target finder program (GenScript, Piscataway, NJ) was used to select CRIP 1a siRNA-target sequences. CRIP 1a N18TG2 cell lines were generated by isolating and expanding G418-resistent single colonies in selection media containing 600 mg/ml G418 (Gibco/ Life Technologies, Grand Island, NY). Cells were maintained in DMEM/F12 media with 10% heat-inactivated bovine serum, GlutaMax, and P/S, with 0.25 mg/ml geneticin.
For ligand pretreatments, appropriate concentrations of drugs were added to treatment media (DMEM, 1% FBS, P/S) and sterile-filtered, and drug treatment media was added to cells for the appropriate time period. To terminate drug treatments, cells were rinsed twice for 2 minutes with warm rinse media (DMEM, 1% FBS), and harvested for assays.
Membrane Homogenate Preparation
Cells were harvested in phosphate-buffered saline with 0.4% (w/v) EDTA or by gentle scraping and centrifuged at 1000g for 10 minutes to remove media. Cells were homogenized in ice-cold 50 mM Tris-HCl, 3 mM MgCl 2 , and 1 mM EGTA, pH 7.4 (membrane buffer), and centrifuged at 50,000g for 10 minutes. The resulting pellets were homogenized in 50 mM Tris-HCl, 3 mM MgCl 2 , 0.2 mM EGTA, pH 7.4 (TME buffer) with 100 mM NaCl, and protein content was determined.
Cerebella were obtained from adult male Sprague-Dawley rats (Harlan, Indianapolis, IN). Rats were sacrificed by rapid decapitation, brains were removed, and cerebella were dissected on ice. Cerebellum samples were homogenized in membrane buffer and membranes were isolated by centrifugation as described above. Experiments were performed with the approval of the Institutional Animal Care and Use Committee at Virginia Commonwealth University in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, 7th Edition.
CRIP 1a Generation, Purification, and Determination of Stoichiometry
A CRIP 1a cDNA insert was subcloned into the BamHI and XhoI sites of the pGEX-4T-1 vector (GE Healthcare, Piscataway, NJ) to generate a glutathione S-transferase (GST)-tagged CRIP 1a (GST tag-thrombin cleavage site-CRIP 1a ) construct. Plasmid DNA encoding GST-tagged CRIP 1a was transformed into Escherichia coli BL21-DE3-competent cells. E. coli were grown to optical density 600 5 0.6 from a single colony and then GST-tagged CRIP 1a expression was induced via addition of isopropyl thiogalactoside (1 mM) for 6 hours. E. coli were collected via centrifugation (1000g, 10 minutes, 4°C) and a bacterial lysate produced via sonication with lysozyme (25 mg/ml). CRIP 1a induction and solubility tests were performed by polyacrylamide gel electrophoresis on harvested lysates using 10% polyacrylamide gels, which were stained with Coomassie blue to verify protein expression. Crude lysate was then separated into soluble and insoluble lysates. GST-tagged CRIP 1a was isolated from bacterial lysate using a GSTrap FF column (Amersham Biosciences, Piscataway, NJ) as follows. The column was equilibrated with binding buffer [0.1 M phosphate buffered saline (PBS)], bacterial lysate was added to allow GST-CRIP binding, the column was washed (PBS), and the GST tag was cleaved via thrombin (500 units in 0.5 ml PBS). Following elution with PBS, CRIP 1a was purified by the subsequent removal of thrombin using HiTrap benzamidine column purification. Briefly, the column was equilibrated with binding buffer (0.05 M Tris-HCl, 0.5 M NaCl, pH 7.4) and then the sample was added to the column followed by elution with binding buffer. CRIP 1a eluates were collected and pooled, and CRIP 1a pools and a BSA protein standard curve were subjected to polyacrylamide gel electrophoresis using 15% polyacrylamide gels, and visualized by Coomassie blue stain. Stained gel images were captured via ImageJ, and CRIP 1a concentration was determined by subsequent linear regression analysis (Windows Excel). Purified CRIP 1a concentration curves were then generated in tandem with hCB 1 -HEK (6CRIP 1a ) cell membrane preparations or rat cerebellar membranes to determine CRIP 1a concentration via immunoblot analysis on 15% polyacrylamide gels. From these data, the stoichiometric relationship between CRIP 1a concentration in cell membranes and CB 1 R levels, determined by [ 3 H]SR141716A B max values, was calculated.
Immunoblotting
Samples (70 mg) of cell membrane homogenates or purified CRIP 1a standards were added to sample buffer (1 M Tris-HCl, 20% SDS, 1 M dithiothreitol, 60% sucrose, bromophenol blue) and boiled for 10 minutes. Samples were loaded into 15% SDS polyacrylamide gels, and electrophoresis was conducted at 120 V for 1.5 hours. Proteins were transferred by electrophoresis onto polyvinylidene difluoride membranes at 70 V for 70 minutes. Blots were blocked for 1 hour at room temperature with 5% (w/v) nonfat dry milk and then rinsed with Tris-buffered saline with 0.1% (v/v) Tween-20 (TBST). Primary antibody (rabbit anti-CRIP 1a antiserum 077.4; 1:500; Niehaus et al., 2007) was incubated overnight at 4°C, followed by TBST rinse. Secondary antibody (LI-COR goat anti-rabbit 800 CW IR dye, 1:5,000) was then incubated at room temperature for 1 hour, followed by TBST rinse. Blots were visualized with the LI-COR Odyssey system. in TME with 0.5% (w/v) BSA, in a total volume of 0.5 ml with and without 5 mM unlabeled SR141716A to determine nonspecific binding. The assay was incubated for 90 minutes at 30°C and terminated by vacuum filtration through GF/B glass fiber filters that were presoaked in Tris buffer containing 0.5% (w/v) BSA. Bound radioactivity was determined using liquid scintillation spectrophotometry at 45% efficiency for [ 3 H]CP55,940 in TME (without NaCl) with 0.5% (w/v) BSA, in a total volume of 0.5 ml with and without 5 mM unlabeled SR141716A to determine nonspecific binding. The assay was incubated for 90 minutes at 30°C and terminated by vacuum filtration through GF/B glass fiber filters that were presoaked in Tris buffer containing 0.5% (w/v) BSA. Bound radioactivity was determined using liquid scintillation spectrophotometry at 45% efficiency for [ [
S]GTPgS Binding
Cell membrane preparations (10 mg of protein) were incubated with various drugs, 100 mM NaCl, 0.1% BSA, 10 mM (CB 1 -HEK), or 20 mM (N18TG2) GDP and 0.1 nM [ 35 S]GTPgS in TME in 0.5-ml total volume, for 2 hours at 30°C. In some experimental conditions, 100 mM NaCl was omitted to increase constitutive receptor activity. Basal binding was assessed in the absence of agonist, and nonspecific binding was measured with 10-mM unlabeled GTPgS. The reaction was terminated by vacuum filtration through GF/B glass fiber filters. Bound radioactivity was determined by liquid scintillation spectrophotometry at 95% efficiency for [ Briefly, 2 pmol of AEA-d 8 and 2 nmol 2AG-d 8 as deuterated internal standards were added to each sample. The endocannabinoids were extracted from the samples with 3 volumes chloroform/methanol (2:1, v/v containing 34.8 mg phenylmethanesulfonyl fluoride/ml) and a 0.73% (w/v) sodium chloride mixture. The organic phases from the three extractions were pooled and the organic solvents were evaporated to dryness with nitrogen. Dried samples were reconstituted in 100 ml of chloroform and mixed with 1 ml of cold acetone to precipitate proteins. The mixtures were centrifuged and the upper layers were collected and evaporated to dryness with nitrogen. The extracts were reconstituted with 100 ml of methanol and placed in autosample vials for liquid chromatography-electrospray ionization-tandem mass spectrometry analysis. The AEA and 2-AG were separated and detected using a Shimadzu SCL HPLC system (Kyoto, Japan) with a Discovery HS C18 Column 15 cm Â 2.1 mm, 3 mm (Supelco/Sigma-Aldrich, Bellefonte, PA) kept at 40°C and an Applied Biosystems 3200 Q trap with a turbo V source for TurbolonSpray (Ontario, Canada) run in multiple reaction monitoring mode. The mobile phase consisted of 10:90 water/methanol with 0.1% (w/v) ammonium acetate and 0.1% (v/v) formic acid. The flow rate was 0.3 ml/min and total run time was 10.00 minutes. The injection volume was 20 ml and the autosampler temperature was set at 5°C. The mass spectrometer was run in electrospray ionization positive mode. Ions were analyzed in multiple reaction monitoring mode and the following transitions were monitored: (348 . 62) and (348 . 91) for AEA; (356 . 62) for AEA-d 8 ; (379 . 287) and (379 . 269) for 2-AG; (387 . 96) for 2AG-d 8 . The standard curves for the samples were 0.039-1.25 pmol AEA and 0.06-2.0 nmol 2-AG. The limit of detection and limit of quantification were set at 0.039 pmol for AEA and 0.063 nmol for 2-AG.
Hippocampal Culture Preparation
All procedures used in this study were approved by the Animal Care Committee of Indiana University and conform to the Guidelines of the National Institutes of Health on the Care and Use of Animals. Mouse (CD1 strain) hippocampal neurons isolated from the CA1-CA3 region were cultured on microislands as described previously (Furshpan et al., 1976; Bekkers and Stevens, 1991) . Neurons were obtained from animals (age postnatal day 0-2) and plated onto a feeder layer of hippocampal astrocytes that had been laid down previously (Levison and McCarthy, 1991) . Cultures were grown in high glucose (20 mM) DMEM containing 10% horse serum, without mitotic inhibitors and used for recordings after 8 days in culture and for no more than 3 hours after removal from culture medium.
Electrophysiology
When a single neuron is grown on a small island of permissive substrate, it forms synapses-or "autapses"-onto itself. All experiments were performed on isolated autaptic neurons. Whole cell voltage-clamp recordings from autaptic neurons were carried out at room temperature using an Axopatch 200A amplifier (Axon Instruments, Burlingame, CA). The extracellular solution contained (in mM) 119 NaCl, 5 KCl, 2.5 CaCl 2 , 1.5 MgCl 2 , 30 glucose, and 20 HEPES. Continuous flow of solution through the bath chamber (∼2 ml/min) ensured rapid drug application and clearance. Drugs were typically prepared as stocks, and then diluted into extracellular solution at their final concentration and used on the same day.
Recording pipettes of 1.8-3 MV were filled with (in mM) 121.5 potassium gluconate, 17.5 KCl, 9 NaCl, 1 MgCl 2 , 10 HEPES, 0.2 EGTA, 2 MgATP, and 0.5 LiGTP. Access resistance and holding current were monitored and only cells with both stable access resistance and holding current were included for data analysis. Conventional stimulus protocol: The membrane potential was held at -70 mV and excitatory postsynaptic currents (EPSCs) were evoked every 20 seconds by triggering an unclamped action current with a 1.0-millisecond depolarizing step. The resultant evoked waveform consisted of a brief stimulus artifact and a large downward spike representing inward sodium currents, followed by the slower EPSC. The size of the recorded EPSCs was calculated by integrating the evoked current to yield a charge value (in pC). Calculating the charge value in this manner yields an indirect measure of the amount of neurotransmitter released, at the same time minimizing the effects of cable distortion on currents generated far from the site of the recording electrode (the soma). Data were acquired at a sampling rate of 5 kHz. DSE Stimuli. After establishing a 10-to 20-second 0.5 Hz baseline, DSE was evoked by depolarizing to 0 mV for 50 milliseconds, 100 milliseconds, 300 milliseconds, 500 milliseconds, 1 second, 3 seconds, and 10 seconds, followed in each case by resumption of a 0.5-Hz stimulus protocol for 20-801 seconds, allowing EPSCs to recover to baseline values. This approach allowed us to determine the sensitivity of the synapses to DSE induction.
Transfection of Autaptic Cultures
Neurons were transfected using a modified calcium phosphatebased method (Jiang et al., 2004) . Briefly, plasmids for hemagglutinin (HA)-tagged CRIP 1a and for the fluorescent marker mCherry (2 mg/well) were combined with 2 M CaCl 2 and gradually added to HEPES-buffered saline; the mixture was added to the serum-free neuronal media. Coverslips were incubated with this mixture in a separate well for 2.5 hours and extra media was placed in a 10% CO 2 incubator to induce equilibration. At the end of 2.5 hours, the reaction mixture was replaced with acidified serum-free media for 20 minutes. After this, cells were returned to their home wells.
Immunostaining of Autaptic Cultures
Autaptic neurons cultured on coverslips were transfected and prepared as described previously ). Briefly, paraformaldehyde-fixed neurons were incubated with an HA11 antibody overnight at 4°C and then washed six times with 0.1 M PBS. Cells were next incubated with fluorescein isothiocyanate-conjugated donkey secondary antibody (anti-mouse, 1:100; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) for 1.5 hours at room temperature. Finally coverslips were washed, dried, and mounted. Images were acquired with a Leica TCS SP5 confocal microscope (Leica Microsystems) using Leica LAS AF software and a 63Â oil objective. Images were processed using ImageJ (available at http://rsbweb.nih.gov/ij/) and/ or Photoshop (Adobe Inc., San Jose, CA).
Immunostaining of Rat Brain Sections
Tissue preparation and immunofluorescence labeling were conducted as described (Falenski et al., 2007) with minor modification. Adult male Sprague-Dawley rats (200-250 g) (Harlan) were housed on a 12-hour light/dark cycle in single cages and were provided with food and water ad libitum. Rats were injected with ketamine/xylazine (75 mg/kg, i.p.), flushed transcardially with saline, and perfused with 4% paraformaldehyde in 100 mM sodium phosphate buffer (pH 7.4). Brains were removed and postfixed in the same fixative overnight, and then placed in sodium phosphate buffer plus 30% sucrose for cryoprotection. Coronal sections of the cerebellum (20 mm) were cut on a cryostat maintained at -20°C and thaw-mounted onto gelatin-subbed slides. Sections were incubated for 30 minutes in PBS containing 0.1% Triton Â 100 and then for 1 hour in SuperBlock Blocking Buffer (Pierce, Rockford, IL) with 0.1% Triton Â 100. Sections were then incubated with rabbit anti-CRIP 1a -Ct (antiserum 077.4, 1:1000) and guinea pig anti-CB 1 R-Ct (against CB 1 R residues 401-473, 1:1000) in SuperBlock Blocking Buffer for 72 hours, followed by incubation in appropriate secondary antibodies (CRIP 1a , Alexa-488; CB 1 , Alexa-595; 1:200) for 1 hour. Slides were washed, and coverslips were mounted using Vectashield (Vector, Burlingame, CA) and sealed with clear nail polish. Images were captured at 60Â magnification on a Zeiss 700 laser scanning confocal microscope.
For immunolabeling of CRIP 1a with visualization by immunohistochemistry, brains were removed and postfixed in Bouin's fixative for 3 days at room temperature before being embedded in paraffin wax. Coronal sections (10 mm) were cut and mounted on glass slides.
Dewaxed sections were blocked with 5% normal goat serum/PBS with 0.2% Triton X-100 (PBST) and then incubated with 077.4 CRIP 1a antiserum diluted 1:1000 in 5% normal goat serum in PBST. Bound antibodies were revealed by using the avidin-biotin complex, peroxidase method (Vector Laboratories). The specificity of immunostaining was established by testing antisera preabsorbed with the KPNETRSLMWVN-KESFL peptide antigen (20 mM), which comprises the C-terminal region of the rat CRIP 1a protein.
Immunostaining of Mouse Brain Sections
GAD67-GFP mice were generated by Dr. Yuchio Yanagawa [Gunman University, Gunma, Japan (Tamamaki et al., 2003) ]. Brain sections were prepared from mice perfused with 4% paraformaldehyde. Brains were removed and immersed in 30% sucrose for 24-72 hours at 4°C. Tissue was then frozen in a freezing compound (Tissue-Tek O.C.T., VWR, Radnor, PA) and sectioned (15-30 mm) using a Leica CM1850 cryostat (Leica Microsystems). Tissue sections were mounted onto Superfrost Plus slides, washed in PBS, then treated with SEA BLOCK blocking buffer (Thermo Scientific, Rockford, IL). Cells were treated overnight at 4°C with antibodies prepared in PBS and detergent (saponin, 0.1%). Secondary antibodies (Alexa 488, 495, or 647, antimouse, anti-rabbit, or anti-guinea pig as appropriate; Invitrogen, Carlsbad, CA) were subsequently applied overnight at 4°C. Monoclonal synaptic vesicle 2 (SV2) and GAD65 antibodies were obtained from the Developmental Studies Hybridoma Bank (Iowa City, IA) and used at 1:500. The guinea pig CB 1 and CRIP 1a antibodies were developed in house and used at 1:300 and have been described previously (Berghuis et al., 2007; Hu et al., 2010) . Images were acquired with a Leica TCS SP5 confocal microscope (Leica Microsystems) using Leica LAS AF software and a 63Â oil objective. Images were processed using ImageJ (available at http://rsbweb.nih.gov/ij/) and/or Photoshop (Adobe Inc., San Jose, CA). Images were modified only in terms of brightness and contrast.
Data Analysis
Unless otherwise noted, all binding data are reported as mean values 6 standard error of the mean (S.E.M.) of at least three independent experiments performed in duplicate ([ Significance was determined using analysis of variance (ANOVA) and the posthoc Newman-Keuls multiple comparison test for comparison of three or more conditions or by Student's t test for comparison of two conditions. In the few instances where unequal variance between groups was detected by F test, Welch's correction for unequal variance was applied. Two-way ANOVA and the posthoc Bonferroni test were used in experiments comparing two or more sets of independent variables. Results were considered statistically significant when the P value was #0.05. All inferential statistics were performed using GraphPad Prism v5.0d software.
Results
Stoichiometry of CB 1 R and CRIP 1a Expression in Stably Transfected HEK-293 Cells and Rat Cerebellum. Niehaus et al. (2007) previously showed that CRIP 1a localizes to the cell membrane and interacts with the C-terminal tail of CB 1 Rs without affecting CB 1 R expression levels. To confirm that stable coexpression of CRIP 1a did not affect CB 1 R expression and to determine CRIP 1a /CB 1 expression ratios, CB 1 R B max values were obtained using [ 3 H]SR141716A saturation binding analysis (Supplemental Fig. 1 performed. CRIP 1a was purified using GST-pulldown methodology and CRIP 1a concentration curves were included in immunoblots to determine unknown CRIP 1a concentrations (Fig. 1A) . The C-terminally directed CRIP 1a antibody (Niehaus et al., 2007) produced relatively clean blots, with few or no extraneous labeling other than the 18-kDa band corresponding to CRIP 1a (Supplemental Fig. 2 ). Experimentally determined CRIP 1a concentrations were then compared with CB 1 R B max values to determine the molar stoichiometric relationship of CRIP 1a /CB 1 Rs (Table 1) . In CB 1 -HEK cells, the molar ratio of CRIP 1a /CB 1 was less than 1 (0.34 6 0.08), indicating that the CB 1 R is in molar excess relative to CRIP 1a natively expressed in CB 1 -HEK cells. In CB 1 -HEK-CRIP 1a cells, CRIP 1a was in molar excess to the CB 1 R, with a CRIP 1a /CB 1 R ratio of 5.44 6 0.42, which was significantly different from CB 1 -HEK cells. For comparison of expression ratios of CRIP 1a /CB 1 R in a native tissue, [ 3 H]SR141716A saturation analysis and quantitative immunoblotting of CRIP 1a were also conducted in rat cerebellar membranes (Table 1) . Interestingly, rat cerebellum had a CRIP 1a /CB 1 R molar ratio of 32.02 6 4.39, indicating a greater molar excess of CRIP 1a relative to the CB 1 R than in the CB 1 -HEK-CRIP 1a cells. These results demonstrate that membranes from CB 1 -HEK-CRIP 1a cells express a significantly greater molar ratio of CRIP 1a /CB 1 R than CB 1 -HEK cells, but not greater than the ratio obtained in membranes from rat cerebellar homogenates.
The stoichiometry result in rat cerebellum is complicated by the question of whether CRIP 1a is colocalized in the same cells with CB 1 Rs in this tissue. Therefore, to determine whether CB 1 Rs and CRIP 1a are colocalized in rat cerebellum, brain sections were colabeled with rabbit anti-CRIP 1a (green) and guinea pig anti-CB 1 R-Ct (red) antibodies (Fig. 1C) . Colocalization at this level of resolution of CRIP 1a -immunoreactivity (ir) with CB 1 -ir is evident in the molecular layer. CRIP 1a -ir is also evident at lower levels in the granule cell layer, where CB 1 -ir is seldom detected. In the Purkinje cell layer, intense CB 1 R-ir can be seen in putative axon terminals, possibly from basket cells that are presynaptic to the unstained somata of Purkinje cells; little or no CRIP 1a -ir is evident in the axon terminals of basket cells. The widespread but heterogeneous distribution of CRIP 1a among rat cerebellar layers was confirmed by immunohistochemical staining visualized with peroxidase labeling, which was blocked by coincubation with an antigen peptide corresponding to the C-terminal region of CRIP 1a (Supplemental Fig. 3) . These results indicate that in the cerebellum CRIP 1a is putatively colocalized with CB 1 Rs in axonal fibers arising from the glutamatergic granule cells that project throughout the molecular layer, and the granule cell layer also contains CRIP 1a at lower levels.
To determine the localization of CRIP 1a and its colocalization with CB 1 Rs in specific cellular elements of the cerebellum, immunofluorescent labeling was performed in the GAD67-GFP mouse, which expresses green fluorescent protein in GABAergic neurons (Tamamaki et al., 2003) , with costaining of multiple subcellular markers. Using an antibody developed against CRIP 1a (Hu et al., 2010) , we examined the distribution of this protein in multiple cerebellar subregions. CRIP 1a is widely distributed in the cerebellum, abundant in both the molecular and granular layers ( Fig. 2A-C) , similar to what was detected in the rat using an independent antibody in Fig. 1 . In the molecular layer the staining substantially overlaps with SV2, a presynaptic marker (Fig. 2D) , consistent with a presynaptic localization. However, we also observed costaining with GAD67-GFP positive processes, perhaps belonging to Purkinje cells (Fig. 2E) . CRIP 1a was widely colocalized with CB 1 R throughout the molecular layer (Fig. 2F ), but not in the Immunofluorescence staining of CRIP 1a (green) and CB 1 receptor (red), or overlay (yellow) indicates areas of colocalization in rat cerebellum as determined by confocal microscopy. Note the characteristic scarcity of CB 1 R-ir in the granule cell layer (GCL) and colocalization of CB 1 R and CRIP 1a -ir in the molecular layer (ML). Arrows indicate CB 1 R-ir in perisomatic basket cell axon terminals, which are devoid of CRIP 1a -ir. PCL, Purkinje cell layer. Scale bar, 200 mm.
pinceau region near Purkinje cells (e.g., arrowhead Fig. 2F ) where the most intense CB 1 R expression is seen. Higher magnification images in the granule cell layer showed that CRIP 1a is commonly colocalized with CB 1 Rs (Fig. 3A) . Indeed most CRIP 1a puncta overlapped with CB 1 R-ir, although there were some CB 1 R-positive puncta that were not positive for CRIP 1a . The diffuse CRIP 1a staining appeared to correspond to mossy terminal staining as shown by overlap with the brighter SV2 staining (Fig. 3B) . However, the most punctate CRIP 1a staining, seen when mossy terminal staining was allowed to saturate (Fig. 3, B2-B4 ), also partially overlapped with SV2. CRIP 1a staining in the granule cell layer did not colocalize with (Fig. 3C) or GAD67-GFP (data not shown), suggesting that expression is restricted to excitatory cells in the granule layer (Meyer et al., 2002) . It is notable that CRIP 1a is not detected in the pinceau region of basket cell inputs to the Purkinje neurons (Fig. 3D) , an area that is associated with strong CB 1 R expression (e.g., Fig. 2F ). These results indicate widespread colocalization of CRIP 1a with CB 1 Rs in multiple cellular elements of the cerebellum, although CRIP 1a and CB 1 R expression did not completely overlap in all cerebellar subregions examined.
GAD65-ir
Effects of CRIP 1a on CB 1 R-Mediated G-Protein Activation in Stably Transfected HEK-293 Cells. To determine the effects of CRIP 1a on CB 1 R mediated G-protein activity, basal and ligand-modulated [ 35 S]GTPgS binding was conducted in CB 1 -HEK (6CRIP 1a ) cells (Fig. 4) . Concentration-effect curves for a variety of cannabinoid ligands were examined, including the classic phytocannabinoid THC, and its synthetic analogs HU210 and levonantradol; the aminoalkylindole WIN55,212-2; the bicyclic cannabinoid CP55,940; the eicosanoids noladin ether [2-arachidonoylglycerol ether (2-AGE)], a stable analog of 2-AG that is also a putative endocannabinoid, and methanandamide (MAEA), a stable analog of anandamide; and the diarylpyrazole inverse agonist rimonabant, also known as SR141716A. Nonlinear regression fitting of the concentration-effect curves revealed maximal stimulation (E max ) and EC 50 values for each ligand (Table 2) . Results in CB 1 -HEK cells showed that noladin ether, WIN55,212-2 and HU210 appeared to act as full agonists ( Fig. 4; Table 2 ). CP55,212-2 acted as a high efficacy partial agonist relative to 2-AGE, and MAEA and levonantradol were moderate efficacy partial agonists. THC acted as a low efficacy partial agonist and rimonabant acted as an inverse agonist ( Fig. 4; Table 2 ).
In agreement with our previous findings (Niehaus et al., 2007) , stable CRIP 1a expression reduced the apparent inverse agonism of rimonabant compared with CB 1 -HEK cells without CRIP 1a transfection (Fig. 4) , as indicated by a main effect of cell line in two-way ANOVA (cell line Â ligand concentration) of the concentration-effect curves (Table 2 ). This reduction in inverse agonism was attributable to a lesser maximal inhibition of basal G-protein activation by rimonabant in CB 1 -HEK-CRIP 1a than in CB 1 -HEK cells (Table 2) Fig. 4; Table 2 ), as indicated by an effect of cell line in two-way ANOVA. This decrease in agonist-stimulated activity was attributable to a reduction in maximal stimulation (E max ) in CB 1 -HEK-CRIP 1a relative to CB 1 -HEK cells, without any significant differences in EC 50 values between the cell lines (Table 2) .
Interestingly, concentration-effect curves for G-protein activation by the partial agonists MAEA, levonantradol, and THC were unaffected by CRIP 1a overexpression (Fig. 4; Table 2 ). There was no significant effect of cell line in the presence of any of these partial agonists, and neither the E max or EC 50 values of these ligands differed between CB 1 -HEK and CB 1 -HEK-CRIP 1a cells. Because of the differential effect of CRIP 1a on G-protein activation by ligands of different intrinsic efficacies, the relative efficacy relationship among some ligands differed between cell types. In CB 1 -HEK cells the order of descending relative efficacy, on the basis of E max values, was 2-AGE $ HU210 5 WIN55,212-2 $ CP55,940 $ MAEA 5 levonantradol . THC . . rimonabant, whereas in CB 1 -HEK-CRIP 1a cells it was 2-AGE . HU210 . WIN55,212-2 5 CP55,940 5 MAEA 5 levonantradol . THC . . rimonabant.
The (Seifert and Wenzel-Seifert, 2002) . We therefore determined whether CRIP 1a inhibits constitutive receptor activity that is unrestricted by sodium. Results showed that 100 mM NaCl reduced basal [
35 S]GTPgS binding in both CB 1 -HEK and CB 1 -HEK-CRIP 1a cells by .50% relative to the absence of Na 1 (Fig. 5A) , as confirmed by two-way ANOVA (effect of Na 1 , P , 0.0001). To distinguish receptor-mediated from receptor-independent G-protein activity, cells were pretreated with or without pertussis toxin (PTX), which uncouples G i/o -proteins from receptor-stimulated guanine nucleotide exchange (Sunyer et al., 1989) . Na 1 also inhibited basal [
35 S]GTPgS binding by 38% in both cell lines after treatment with PTX (effect of sodium, P , 0.0001), but the effect was diminished relative to untreated cells (Fig. 5B) , P , 0.0001), and there was a significant interaction between Na 1 and CRIP 1a (P 5 0.0346), as indicated by two-way ANOVA (Fig. 6A) . In the absence of Na 1 , WIN55,212-2 had no effect on [
S]GTPgS binding. In contrast, WIN55,212-2 stimulated [
35 S]GTPgS binding in the presence of 100 mM Na 1 (P , 0.05 by Bonferroni posthoc test). The opposite effect of Na 1 was seen with rimonabant ( Fig. 6B ). There was a significant effect of both Na 1 (P 5 0.0024) and CRIP 1a (P 5 0.0466) on net , suggesting that CRIP 1a attenuates both agonist-stimulated and constitutive CB 1 R-mediated G-protein activation in a manner consistent with the effects of Na 1 on basal receptor activity seen in Fig. 5 .
A potential confounding factor in the interpretation of the effects of CRIP 1a on basal CB 1 R-mediated G-protein activity is the possible presence of endocannabinoids in the membrane preparation. To determine whether endocannabinoids could have contributed to basal G-protein activity, mass spectrometric analysis of CB 1 -HEK and CB 1 -HEK-CRIP 1a cells and isolated cell membranes was performed to quantify the two major endocannabinoids, 2-AG and AEA. However, endocannabinoid levels were below the limit of detection for both 2-AG (.0.063 pmol) and AEA (.0.039 nmol) relative to deuterated standards, in extracts of both intact cells and isolated membranes, as determined in analysis of three independent samples. These results indicate that endocannabinoids are unlikely to have contributed to apparent basal CB 1 R-mediated G-protein activity in either cell line.
Effect of CRIP 1a on CB 1 R Desensitization and Downregulation in Stably Transfected HEK-293 Cells. To determine whether CRIP 1a affected the regulation of CB 1 R function by prolonged agonist occupancy, CB 1 -HEK cells with and without stable CRIP 1a cotransfection were pretreated with WIN55,212-2 (10 mM), THC (6 mM), or vehicle for 4 hours, followed by MAEA-stimulated [ Table 2 ). Pretreatment of the cells with WIN55,212-2 or THC decreased CB 1 R-mediated G-protein activation in membranes prepared from either cell line (Fig. 7) . Significantly lower MAEA E max values were seen in WIN55,212-2-pretreated compared with vehicle-pretreated cells with or without CRIP 1a cotransfection (Table 3 ). In contrast, THC pretreatment did not affect MAEA E max values in either cell line. However, pretreatment with either drug significantly increased MAEA EC 50 values (Table 3) . Thus, pretreatment with either WIN55,212-2 or THC apparently desensitized MAEA-stimulated G-protein activity in both cell lines. However, there were no apparent differences in the level of desensitization produced by either ligand between CB 1 -HEK cells with and without stable CRIP 1a cotransfection. Indeed, two-way ANOVA of E max values indicated a significant effect of drug pretreatment (P , 0.0001), but there was no effect of CRIP 1a (P 5 0.306). Likewise, twoway ANOVA of EC 50 values revealed a significant effect of drug pretreatment (P 5 0.0036), but there was no effect of CRIP 1a (P 5 0.848). Subsequent one-way ANOVA with posthoc Newman-Keuls multiple comparison test revealed that neither E max nor EC 50 values of MAEA differed significantly between CB 1 -HEK cells with and without stable CRIP 1a cotransfection after WIN55,212-2 or THC pretreatment. These results indicate that CRIP 1a did not affect cannabinoid-induced CB 1 R desensitization under these conditions. Basal [ 35 S]GTPgS binding was not significantly affected by ligand pretreatment in either cell line (Supplemental Fig. 4 ). Basal [ 35 S]GTPgS binding in vehicle-pretreated cells was 48.9 6 9.2 and 43.9 6 4.2 fmol/mg in cells without and with CRIP 1a coexpression, respectively. There was no significant effect of pretreatment (P 5 0.584) or CRIP 1a expression (P 5 0.547) with regard to basal [
35 S]GTPgS binding, according to twoway ANOVA. Likewise, one-way ANOVA revealed no significant effect of pretreatment in either cell line. These results indicate that the pretreatment ligand was sufficiently removed prior to assay, because residual agonist that might have remained in the membrane preparation from pretreated cells would be predicted to elevate the apparent "basal" level of [
35 S]GTPgS binding. In contrast, CRIP 1a overexpression attenuated cannabinoid ligand-induced CB 1 R downregulation, as determined using the identical pretreatment protocol that was used to examine effects on G-protein activation. Two-way ANOVA of [ 3 H]SR141716A B max values revealed significant effects of ligand pretreatment (P 5 0.0001) but no effect of CRIP 1a expression (P 5 0.199). However, there was a trend toward an interaction between these two factors (P 5 0.06). With regard to [ 3 H]SR141716A K D values, there was no effect of ligand pretreatment (P 5 0.812) or CRIP 1a expression (P 5 0.345), nor was there an interaction (P 5 0.736). In CB 1 -HEK cells, pretreatment with either 10 mM WIN55,212-2 or 6 mM THC decreased the B max value of [ 
CRIP 1a Modulates CB 1 Receptor Signaling and Regulation
Effects of CRIP 1a on CB 1 R-Mediated G-Protein Activation in Stably Transfected N18TG2 Cells. Results in CB 1 -HEK cells with and without stable cotransfection of CRIP 1a indicated that CRIP 1a negatively modulates constitutive and high efficacy agonist-stimulated G-protein activation by CB 1 Rs. To determine whether similar effects could be demonstrated in a neural cell type, mouse neuroblastoma N18TG2 cells, which endogenously express CB 1 Rs, were stably transfected with CRIP 1a . In addition, because N18TG2 cells endogenously express CRIP 1a at moderate levels that are in excess of CB 1 R levels (Supplemental Fig. 5, Table 4 ), cell lines with stable transfection of siRNA against CRIP 1a were also generated. Two cloned cell lines (OX1 and OX5) were isolated that stably overexpressed CRIP 1a mRNA without any alteration in CB 1 R mRNA (Supplemental Fig. 5B ). CRIP 1a clones expressed 8:1 and 7:1 (CRIP 1a /CB 1 R) cDNA ratios, respectively, as compared with a 1:7 ratio in untransfected N18TG2 cells (determined by real-time polymerase chain reaction using eno2 as a standard; Supplemental Fig. 5A ). Comparative immunoblots also indicated greater relative expression of CRIP 1a protein in CRIP 1a -overexpressing clones compared with untransfected N18TG2 cells (Supplemental Fig. 5C ). Likewise, two clones (KD2C and KD2F) were isolated that exhibited siRNA-mediated knockdown of CRIP 1a mRNA relative to untransfected N18TG2 cells, whereas cells transfected with empty siRNA vector did not exhibit CRIP 1a knockdown (Supplemental Fig. 5A ). Immunoblot analysis showed that CRIP 1a protein levels were reduced by 50-60% in siRNA knockdown clones relative to untransfected or vector controltransfected N18TG2 cells (Supplemental Fig. 5C ), but CB 1 R protein levels did not differ between any of these cell models (Supplemental Fig. 5D ).
To determine the precise level of membrane-delimited CRIP 1a protein expression in CRIP 1a -OX N18TG2 clones for comparison with results in CRIP 1a -overexpressing CB 1 -HEK cells, quantitative immunoblots using purified CRIP 1a standards were then conducted in isolated membranes prepared from the two CRIP 1a -transfected clones and untransfected N18TG2 cells. Untransfected N18TG2 cells expressed 0.56 6 0.06 pmol CRIP 1a per mg of membrane protein, whereas clones OX1 and OX5 expressed 1.35 6 0.16 pmol/mg and 1.28 6 0.09 pmol/mg, respectively. The results of CRIP 1a quantitative immunoblots were then compared with B max values derived from cannabinoid radioligand binding assays in control and CRIP 1a -overexpressing N18TG2 cell lines to determine the stoichiometric ratio of CRIP 1a /CB 1 and the effect of CRIP 1a overexpression on CB 1 R B max values. Owing to low CB 1 R expression levels in N18TG2 cells, [ H]CP55,940 binding analysis indicated that CRIP 1a -overexpressing N18TG2 clones have approximately a 2.3-to 2.5-fold increase in both CRIP 1a protein expression and the CRIP 1a /CB 1 expression ratio, in comparison with untransfected N18TG2 cells (Table 4) .
In line with findings from stable CB 1 -HEK-CRIP 1a cells, CRIP 1a overexpression (clones OX1 and OX5) or knockdown (clone KD2C) did not alter the B max values of [ Table 4 ). These results demonstrate altered expression of CRIP 1a protein without altering CB 1 R density in both CRIP 1a -overexpressing and knockdown cells compared with control N18TG2 cells. It is noteworthy to mention that the relative increase in CRIP 1a /CB 1 R ratios in CRIP 1a -overexpressing N18TG2 cells was less than that in the CB 1 -HEK cell models, where CRIP 1a -overexpressing cells showed a 16-fold increase over control cells, as compared with ∼2.5-fold increase in N18TG2-CRIP 1a cells.
To determine whether CRIP 1a overexpression in N18TG2 cells affected constitutive and agonist-stimulated G-protein activation by CB 1 Rs, ligand concentration-effect curves for 35 S]GTPgS binding did not differ significantly between N18TG2 (68.1 6 6.0 fmol/mg), N18-CRIP 1a -KD (66.6 6 16.6), and N18-CRIP 1a -OX cells (70.5 6 5.9 fmol/mg). Results of ligand concentration-effect curves showed that CRIP 1a overexpression decreased WIN55,212-2-and MAEAstimulated [ 35 S]GTPgS binding relative to control N18TG2 cells (Fig. 8, A and B ). There was a significant effect of CRIP 1a knockdown on [ (Fig. 8C) , in contrast to results obtained in the CB 1 -HEK cell models. Accordingly, there were no significant effects of either rimonabant concentration or CRIP 1a expression levels in comparing the rimonabant concentration-effect curves among these three N18TG2 cell lines using two-way ANOVA. Similar results were obtained with all three ligands when comparing ligand-modulated [
35 S]GTPgS binding in the other CRIP 1a -overexpressing (OX5) and knockdown (KD2F) clones to control N18TG2 cells (Supplemental Fig. 6 and Fig. 8) .
Nonlinear regression analysis of the ligand concentrationeffect curves showed that the E max values of both WIN55,212-2 and MAEA were significantly higher in N18-CRIP 1a -KD relative to control N18TG2 cells (Table 5) . Conversely, the WIN55,212-2 E max value was lower in N18-CRIP 1a -OX cells compared with control N18TG2 cells. However, the MAEA E max value did not differ significantly between N18-CRIP 1a -OX cells and control N18TG2 cells, but both WIN55212-2 and MAEA E max values in N18-CRIP 1a -OX cells were significantly lesser than in N18-CRIP 1a -KD cells. In contrast, neither WIN55212-2 nor MAEA EC 50 values were significantly altered by manipulation of CRIP 1a expression levels in these N18TG2 cells lines. Moreover, because two-way ANOVA showed no significant effect of rimonabant concentration in these N18TG2 cell models, curve-fitting analysis was not performed with this ligand. These results indicate that CRIP 1a knockdown enhances whereas CRIP 1a overexpression attenuates agonist-stimulated G-protein activation mediated by CB 1 Rs that are endogenously expressed in N18TG2 neuroblastoma cells.
Potential effects of CRIP 1a on constitutive CB 1 R-mediated G-protein activation could not be determined in the N18TG2 cell models because rimonabant did not significantly inhibit basal [ 35 S]GTPgS binding. It is possible, however, that endocannabinoids present in N18TG2 cells could have obscured the inhibitory effects of rimonabant on basal G-protein activity, perhaps by competing with rimonabant. To address this question, lipid fractions from N18TG2 and N18-CRIP 1a -OX cells, or membranes isolated from each cell line, were analyzed by mass spectrometry to determine the content of 2-AG and AEA. Results showed detectable levels of 2-AG in both intact cells and membrane preparations, although levels on a per-cell basis were approximately 7.5-fold greater in intact cells than isolated membranes (Supplemental Fig. 7) . Importantly, 2-AG levels did not differ between N18TG2 and N18-CRIP 1a -OX cells in fractions prepared from either intact cells or isolated membranes. To determine whether the higher 2-AG levels in intact cells compared with membranes were attributable to greater lipase activity in cells, the cells were incubated in the presence and absence of the diacylglycerol lipase inhibitor tetrahydrolipstatin (orlistat). Results showed that orlistat treatment significantly decreased 2-AG levels in intact cell preparations but not in membranes (Supplemental Fig. 6 ). In intact cells, two-way ANOVA revealed a significant effect of orlistat (P 5 0.032) but not CRIP 1a overexpression (P 5 0.696), and there was no significant interaction between the two factors (P 5 0.768). In isolated membranes, there was only a nonsignificant trend toward an effect of orlistat (P 5 0.105), and there was no effect of CRIP 1a overexpression (P 5 0.574) and no interaction between the two factors (P 5 0.860). AEA levels were detectable in intact cells but were approximately 0.02% of the levels detected for 2-AG, or approximately 0.01 pmol/10 7 cells (data not shown). Two-way ANOVA revealed no effects of either CRIP 1a overexpression (P 5 0.540) or orlistat (P 5 0.452), and there was no significant interaction (0.791). AEA levels in membrane preparations were below the limit of detection. These results suggest that differences in endocannabinoid levels were not responsible for the lack of inhibitory effects of rimonabant in membrane preparations from N18TG2 cells with and without overexpression of CRIP 1a .
Effects of CRIP 1a on Endocannabinoid Signaling in Hippocampal Neuronal Cultures. Results from both HEK-293 and N18TG2 cell models indicate that CRIP 1a can negatively modulate agonist-stimulated CB 1 R activity at (Niehaus et al., 2007) . Therefore, the effects of CRIP 1a overexpression on synaptic function of CB 1 Rs were examined in a more CNS-relevant model. Autaptic hippocampal neurons express all the components of a functional cannabinoid signaling system, including presynaptic CB 1 Rs, depolarization-dependent production of endocannabinoids, probably 2-AG (Straiker and Mackie, 2005) , and monacylglycerol lipase, which hydrolyzes 2-AG and thereby controls the duration of cannabinoid signaling . To assess whether CRIP 1a can functionally interact with this endogenous cannabinoid signaling system, CRIP 1a was overexpressed in autaptic neurons. The distribution of CRIP 1a protein was determined in transfected neurons using an HA11 antibody against the HA tag on the CRIP 1a protein, and results showed that CRIP 1a was widely expressed throughout the transfected neuron (Fig. 9A) . This widespread cellular localization was similar to that of endogenous CRIP 1a (Fig. 9 , B and D; compare with Figs. 1, 2, and 3) . Although endogenously expressed CB 1 R appeared to be primarily limited to neuronal processes and putative autaptic terminals (Fig. 9, B and E), endogenous CRIP 1a was widely colocalized in these cellular elements with CB 1 Rs (Fig. 9, B and F) . These results suggest that CRIP 1a is spatially positioned in a manner such that it could modulate CB 1 R function.
To determine whether CRIP 1a overexpression altered the sensitivity of DSE induction in these autaptic hippocampal neurons, depolarization duration-response curves were obtained. Neurons were depolarized for progressively longer durations (50 milliseconds, 100 milliseconds, 300 milliseconds, 500 milliseconds, 1 second, 3 seconds, and 10 seconds) and the resulting CB 1 R-dependent inhibition was measured. Results showed that the depolarization duration-response curve in CRIP 1a -overexpressing neurons differed substantially from that of control conditions, with a diminished inhibition at 1-, 3-and 10-second depolarizations (Fig. 10, A and B ; P , 0.05 by Bonferroni posthoc test after two-way ANOVA).
2-AG is a strong candidate to serve as the endocannabinoidmediating DSE at autaptic hippocampal synapses Mackie, 2005, 2009; Jain et al., 2013) . Therefore, the response in CRIP 1a -transfected neurons to 2-AG was examined to determine whether sensitivity to exogenously added 2-AG was diminished to the same degree as was DSE. Figure 10C shows that inhibition of EPSCs by 2-AG (5 mM) was substantially attenuated in CRIP 1a -overexpressing neurons relative to controls [relative EPSC charge with 2-AG (5 mM) treatment in wild-type neurons: 0.34 6 0.03, n 5 4; in CRIP 1a -transfected neurons: 0.82 6 0.06, n 5 7; P , 0.05 by unpaired t test]. We have previously reported that anandamide activates CB 1 Rs to inhibit neurotransmitter release in excitatory and inhibitory autaptic neurons Mackie, 2005, 2009) . Thus, the hydrolysis-resistant analog MAEA was tested under control and CRIP 1a -transfected conditions. As with 2-AG, CRIP 1a overexpression also diminished MAEA signaling [ Fig. 10C ; relative EPSC charge with MAEA (5 mM) treatment in wild-type neurons: 0.57 6 0.03, n 5 4; in CRIP 1a -transfected neurons: 0.91 6 0.11, n 5 5; P , 0.05 by unpaired t test]. To determine whether CRIP 1a over expression would suppress constitutive inhibition of EPSCs by CB 1 Rs, the effects of rimonabant (100 nM) were examined. However, no effect of this inverse agonist was detected regardless of whether CRIP 1a was overexpressed (data not shown), as previously reported for nontransfected hippocampal autaptic cultures (Straiker et al., 2012) .
To ascertain whether CRIP 1a transfection interfered more generally with G i/o -mediated modulation of neurotransmission, inhibition by the adenosine A 1 receptor agonist cyclopentyladenosine (CPA) was examined, because it was previously found to robustly inhibit EPSCs in autaptic hippocampal neurons (Straiker et al., 2002) . Figure 10C shows that CRIP 1a overexpression did not interfere with CPA responses [relative EPSC charge after treatment with CPA (100 nM) in control neurons: 0.27 6 0.03, n 5 10; in CRIP 1a -transfected neurons: 0.29 6 0.06, n 5 4]. Together, these results indicate that CRIP 1a attenuates the inhibition of excitatory synaptic transmission by endocannabinoids, and that this action of CRIP 1a is selective for modulation of synaptic transmission by CB 1 Rs.
Discussion
This study extends the findings that CRIP 1a attenuates constitutive inhibition of Ca 21 channels by CB 1 Rs in cotransfected SCG neurons (Niehaus et al., 2007 1 but not in the presence of Na 1 or in PTX-pretreated cells, further indicating that CRIP 1a inhibits CB 1 R constitutive activity. There was an opposing effect of Na 1 on agonist-versus inverse agonist-modulated G-protein activity such that inverse agonism was maximized in the absence of Na 1 , a condition under which PTX-sensitive basal G-protein activity was highest. Conversely, agonist-stimulated G-protein activation was maximized by 100 mM Na 1 , a condition under which PTX-sensitive basal G-protein activation was minimal. CRIP 1a overexpression suppressed the inverse agonist activity of rimonabant in the absence of Na 1 , whereas CRIP 1a only suppressed agonist-stimulated G-protein activation with Na 1 present. The absence of endocannabinoids in CB 1 -HEK membranes suggests that CRIP 1a effects did not result from dampening endocannabinoid tone. Altogether, these results indicate that CRIP 1a overexpression inhibits constitutive and agoniststimulated G-protein activity in CB 1 -HEK cells in a manner consistent with the behavior of receptor G-protein complexes under the allosteric modulatory influence of Na 1 (Seifert and Wenzel-Seifert, 2002) .
If CRIP 1a regulates constitutive activity of CB 1 Rs in vivo, then it can be hypothesized to modulate both cellular trafficking of CB 1 Rs and pharmacological responses to inverse agonists. Constitutive activity may be required for CB 1 R internalization and targeting to presynaptic terminals (Leterrier et al., 2004 (Leterrier et al., , 2006 , although this has been disputed (McDonald et al., 2007) . However, confirmation of constitutive CB 1 R activity in the CNS has been elusive. For example, rimonabant concentrations necessary to depress basal G-protein activity in brain are greater than those required to antagonize CB 1 agonist-stimulated activity (Sim-Selley et al., 2001) , and high rimonabant concentrations decrease basal G-protein activity in CB 1 R knockout mice (Breivogel et al., 2001) . CRIP 1a overexpression inhibits constitutive CB 1 R activity in CB 1 -HEK cells, so it is possible that CRIP 1a contributes to the low level of constitutive activity in the brain. This would be consistent with our finding that inverse agonism by rimonabant was not detected in N18TG2 cells, where endogenous CRIP 1a might suppress constitutive CB 1 R activity. Although siRNA-mediated knockdown of CRIP 1a did not significantly enhance inverse agonism by rimonabant in N18TG2 cells, this finding could result from the low CB 1 R expression level and the fact that rimonabant was only examined in the presence of 100 mM Na 1 in these cells. Inhibition of basal [ 35 S]GTPgS binding by rimonabant in N18TG2 cells is minimal with Na 1 present but detectable after replacement of Na 1 with K 1 (Meschler et al., 2000) . Thus, these neural cell models will be useful to investigate CB 1 R inverse agonism and the role of endogenous CRIP 1a using varying cation concentrations in future studies.
The present study also confirmed that differences in CRIP 1a expression do not influence total CB 1 R expression levels or ligand binding affinity (Niehaus et al., 2007) in both HEK-293 and N18TG2 cell models, despite the use of different radioligands in each cell line. The finding of similar results with both antagonist/inverse agonist ([ 3 H]SR141716A) and agonist ([ 3 H]CP55,940) radioligands suggests that CRIP 1a might influence CB 1 R signaling efficacy without affecting the formation of high-affinity receptor G-protein complexes, which will be addressed in future studies.
The effect of CRIP 1a on CB 1 R-mediated G-protein activation was dependent on the stoichiometric relationship between CRIP 1a and CB 1 Rs. In CB 1 -HEK cells, stable CRIP 1a transfection increased the CRIP 1a /CB 1 R expression ratio from ,0.5 to approximately 7. In N18TG2 cells, which endogenously express both proteins, CRIP 1a transfection increased the ratio of CRIP 1a /CB 1 R from approximately 2 to 5. Importantly, CRIP 1a expression levels in both overexpressed cell lines were lower than in rat cerebellum, suggesting that these cells do not express supraphysiological CRIP 1a levels relative to native tissues. Whether the ratio of overexpressed CRIP 1a /CB 1 R is supraphysiological is difficult to ascertain because CRIP 1a was more widely distributed throughout rat and mouse cerebellum than CB 1 Rs, although colocalization was observed throughout the molecular and granule cell layers.
A major finding of the present study is that CRIP 1a overexpression attenuated cannabinoid agonist-stimulated G-protein activation in both CB 1 -HEK and N18TG2 cells. This was probably not the result of unnaturally overexpressed levels of CRIP 1a because the opposite effect-enhancement of agonist-stimulated G-protein activity-was observed with siRNA-mediated knockdown of CRIP 1a in N18TG2 cells. CRIP 1a knockdown was not examined in CB 1 -HEK cells because CB 1 Rs were more highly expressed than CRIP 1a in this model. Although the inhibitory effect of CRIP 1a overexpression on maximal agonist-stimulated G-protein activation was moderate (∼20-40%) in either cell line, a robust effect of CRIP 1a was observed when comparing N18TG2 cells with CRIP 1a knocked down versus overexpressed, whereby up to a 2.5-fold difference in agonist E max values was observed. These results indicate that CRIP 1a exerts a dramatic effect on CB 1 R-mediated G-protein signaling under appropriate stoichiometric conditions. Moreover, CRIP 1a overexpression in autaptic hippocampal neurons attenuated both DSE and inhibition of excitatory synaptic currents by 2-AG and MAEA, demonstrating that CRIP 1a can regulate one of the most critical functions of CB 1 Rs in neurons. In addition, CRIP 1a overexpression did not alter synaptic inhibition by an adenosine A 1 agonist, suggesting that CRIP 1a selectively modulates CB 1 R activity without altering activity of other GPCRs. Altogether, these results suggest that CRIP 1a could be an important modulator of endocannabinoid signaling in the CNS.
The effects of CRIP 1a on CB 1 R-mediated G-protein activation were also found to be ligand-dependent in CB 1 -HEK cells. CRIP 1a overexpression inhibited G-protein activation by agonists of high intrinsic efficacy, including 2-AGE, WIN55,212-2, HU-210, and CP55,940, but not ligands of lower intrinsic efficacy, including MAEA, levonantradol, and THC. This effect was probably not related solely to chemotype because HU-210 and THC are classic cannabinoids, whereas 2-AGE and MAEA are eicosanoids, yet CRIP 1a only affected the ligand with highest intrinsic efficacy in each class. It is possible that association of CRIP 1a with CB 1 Rs is modulated by the presence of bound ligand in an efficacy-dependent manner. This ligandselective action of CRIP 1a was also dependent on cell type, because CRIP 1a attenuated signaling induced by MAEA in both N18TG2 cells and hippocampal neurons but not CB 1 -HEK cells. Thus, the effects of CRIP 1a on CB 1 R-G-protein interactions could be dependent on G-protein subtype, which varies among cell types (Atwood et al., 2011) . Previous work demonstrated differential association of distinct Ga i/o subtypes with CB 1 Rs occupied by different ligands (Mukhopadhyay and Howlett, 2005) and differential abilities of different ligands to activate purified G i versus G o (Glass and Northup, 1999) . In addition, different Ga i/o subtypes interact selectively with either the C-terminus or third intracellular loop of the CB 1 R (Mukhopadhyay and Howlett, 2001; Anavi-Goffer et al., 2007) , so CRIP 1a association with the CB 1 R Cterminus (Niehaus et al., 2007) might differentially interfere with G-protein association with these distinct intracellular domains of the CB 1 R. Because the C-terminus serves as a docking site for multiple protein-protein interactions (Howlett et al., 2010; Smith et al., 2010) , the effects of CRIP 1a on CB 1 R-G-protein interactions might depend on both ligand occupancy of the receptor and the presence of additional interacting proteins.
The CB 1 R C-terminus interacts with proteins that mediate desensitization and downregulation. For example, probable G-protein-coupled receptor kinase phosphorylation sites have been identified Jin et al., 1999; Daigle et al., 2008) and isolated fragments of the CB 1 R C-terminus can bind to b-arrestins (Singh et al., 2011; Bakshi et al., 2007) and GASP1 (Martini et al., 2007) . Prolonged agonist exposure downregulates CB 1 Rs expressed in HEK-293 (Shapira et al., 2003) but not N18TG2 cells (McIntosh et al., 1998) . Therefore, we examined the effects of prolonged agonist exposure in CB 1 -HEK cells, with and without CRIP 1a overexpression, on CB 1 R levels and agonist-induced activation of G-proteins. Interestingly, our results showed that CRIP 1a overexpression interfered with CB 1 R downregulation (degradation) but not desensitization (uncoupling from G-protein activation). These findings suggest that CRIP 1a might interfere with GASP1 association with CB 1 Rs (Martini et al., 2007 (Martini et al., , 2010 ) or with C-terminal CB 1 R phosphorylation at sites that mediate internalization (Jin et al., 1999; Daigle et al., 2008; ) but not at sites that mediate desensitization (Jin et al., 1999; Morgan et al., 2014) . Regional differences in CB 1 R downregulation after repeated cannabinoid administration have been observed in the CNS of rodents (Sim-Selley, 2003; Sim-Selley et al., 2006) and humans (Villares, 2007; Hirvonen et al., 2012) . Thus, differential colocalization of CB 1 Rs with CRIP 1a could contribute to regional differences in CB 1 R downregulation, and might thereby influence the development of differential tolerance to distinct pharmacological effects of cannabinoids.
The present study provides evidence that CRIP 1a attenuates constitutive and agonist-induced G-protein activation by CB 1 Rs in two distinct cell lines, HEK-293 and N18TG2. Additionally, CRIP 1a inhibits DSE in autaptic hippocampal neurons, suggesting that CRIP 1a modulates the physiologic actions of endocannabinoids in the CNS. These results indicate that CRIP 1a is a negative regulator of acute CB 1 R-mediated G-protein signaling. CRIP 1a also attenuated agonist-induced CB 1 R downregulation, suggesting that it might oppose the development of cannabinoid tolerance. Thus, CRIP 1a could play an important regulatory role in the endocannabinoid system by differentially modulating acute versus chronic activation of CB 1 Rs. Fig. 10 . Overexpression of CRIP 1a diminishes CB 1 -mediated DSE in autaptic hippocampal neurons. (A) DSE time-courses for wild-type (WT; red) versus CRIP 1a transfected neurons (black) in response to 3-second depolarization (arrow). Insets show sample EPSCs from control (1), maximal DSE inhibition (2), and recovery (3) for CRIP 1a -transfected (left) and WT (right) neurons. (B) "Dose" response for DSE using a range of depolarizations from 50 milliseconds to 10 seconds. The wild-type DSE dose response is shown for comparison. *P , 0.05 Bonferroni posthoc test, two-way ANOVA. (C) Bar graph shows relative EPSC charge (1.0 = baseline, no inhibition) after treatment with three drugs under WT and CRIP 1a -transfected conditions: CPA, 100 nM; 2-AG (5 mM); MetAEA (5 mM). *P , 0.05, unpaired t test.
Note Added in Proof
A recently published article by some of the coauthors of this paper showed that manipulation of CRIP 1a expression in N18TG2 cells modulated constitutive and agonist-stimulated extracellular signal-regulated kinase 1/2 phosphorylation by the CB 1 R, and that CB 1 R coupling to Ga o and Ga i 3 was attenuated, whereas coupling to Ga i 1 and 2 was enhanced, by overexpression of CRIP 1a (Blume et al., 2015) .
